| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, January 21, 2020 GlaxoSmithKline, in the midst of sorting out its massive consumer health venture with Pfizer, has run into issues with one of its best-selling consumer brands. It has voluntarily halted production and distribution of Excedrin after manufacturing issues put the quality of some of the pain meds into question. |
|
|---|
|
Top Stories Of The Week Tuesday, January 21, 2020 Hutchison China MediTech has stopped a phase 3 trial of surufatinib in pancreatic neuroendocrine tumors early for positive efficacy. An independent data monitoring committee found the trial had hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval. With tens of billions of dollars in revenue each year, the largest publicly traded U.S. pharmaceutical companies answer drug-pricing critics by pointing to their hefty investments in research and development. But they answer to some of the most powerful institutional investors, too—and those shareholders reaped rich rewards in 2019. Friday, January 17, 2020 SAN FRANCISCO—Cancer is clearly a major medical and societal issue: a major killer that, while predominately affecting the older population, can strike the young through a mixture of environmental factors or a genetic lottery. It’s no wonder we struggle to even call it by its name, preferring just the "big C." Friday, January 17, 2020 SAN FRANCISCO—It was one year ago that GlaxoSmithKline nabbed Tesaro, bringing on Zejula. But don’t expect it to spring for more commercial-stage oncology products anytime soon. While “we are not excluding the opportunity” for products on the market, it “has to be a good fit for the situation," said Axel Hoos, SVP of Oncology R&D. Friday, January 17, 2020 A new study showed that by employing secondary signals from heart rates, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu in real time and better than current infectious disease surveillance methods. Friday, January 17, 2020 After racing out to a fast start in its first year on the market, Novo Nordisk's GLP-1 diabetes superstar Ozempic is already proving a darling for the Danish drugmaker. Now, a heart-helping FDA approval will likely spell even more success for the standout—and bodes well for Novo's other much-touted diabetes launch. Tuesday, January 21, 2020 LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. Friday, January 17, 2020 With regulator scrutiny of AbbVie and Allergan's $63 billion merger likely in its final days, both companies will soon face the arduous task of meshing into a single firm. But that process could take awhile and leave some opportunities for challengers to snag market share—or so they hope. Wednesday, January 22, 2020 Microbes that live in the gut are believed to play an important role in human metabolism. Kintai Therapeutics, a Flagship Pioneering portfolio company, says its drug candidate that leverages the microbiome showed sustained weight loss, as well as markers of improved glucose control and liver health in rodents. Tuesday, January 21, 2020 When the FDA approved Eli Lilly and Boehringer Ingelheim's Jardiance as a heart-helping addition for heart failure patients, it kicked off an arms race in the SGLT2 class. That war for supremacy isn't without reason: The heart failure market is set for a gold rush in the coming years, and it could spell blockbuster sales for drugmakers that come on board. | | [Webinar] InCrowd’s 2020 Healthcare Predictions Tuesday, February 11 | 1pm ET / 10am PT How will 2020 change US healthcare? InCrowd’s physicians weigh in on what the new year will bring. Join Diane Hayes, PhD, InCrowd Co-Founder and Board Member and Daniel S. Fitzgerald, InCrowd CEO and President, for InCrowd’s 2020 Healthcare Predictions Webinar. Register Now! |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|---|
|
Resources Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Sponsored by: DocuSign A digital transformation is taking place in the life sciences industry, from research laboratories to manufacturing facilities. But there has always been a gap in these technologies. Download the whitepaper to learn how this challenge was addressed. Sponsored by: DocuSign This paper discusses some of the challenges that the GDPR will introduce, with a particular focus on its requirements for obtaining verifiable, unambiguous consent. Sponsored by: DocuSign Download this paper to learn how you can fully digitize all paper processes. By doing so, you will see shorter cycle times, reduced development costs, and greater customer satisfaction. Sponsored by: Benchling As emerging modalities transform the needs of life science R&D, how can biotech and pharma companies use modern software approaches to increase productivity and reach breakthroughs faster? Sponsored by: ICON Clinical Research Ltd The beginning of this digital transformation is well underway and is likely to accelerate. Read our white paper, “Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D,” to learn more. Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: EVERSANA How are your launch strategies can convert “innovation” into value for patients? Sponsored by: Colorcon Learn more: Best practices for defending supply chain security and compliance by efficiently managing product authentication. Sponsored by: Metabolon Small or emerging pharmaceutical and biotech companies pursuing novel molecules and targets have two important goals: achieve clinical success and attract new rounds of funding. While there’s never a guarantee of either, certain actions can influence the outcome in your favor. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 